Authors: HOFFMANN R MULLER I NEUBER K LASSMANN S BUER J PROBST M OEVERMANN K FRANZKE A KIRCHNER H GANSER A ATZPODIEN J

Citation: R. Hoffmann et al., RISK AND OUTCOME IN METASTATIC MALIGNANT-MELANOMA PATIENTS RECEIVING DTIC, CISPLATIN, BCNU AND TAMOXIFEN FOLLOWED BY IMMUNOTHERAPY WITH INTERLEUKIN-2 AND INTERFERON ALPHA2A, British Journal of Cancer, 78(8), 1998, pp. 1076-1080